The 30-second answer
MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, discovered in 2015 at USC. It activates AMPK, the master metabolic switch, and animal studies show consistent improvements in insulin sensitivity, exercise capacity, and cardiac function. As of April 2026 there are zero completed human dosing trials of the native peptide. The first one, NCT07505745, began recruiting in February 2026 and reads out around 2028. Every dosing protocol in circulation is allometric scaling from mouse intraperitoneal injection. WADA prohibits it at all times. The deficiency narrative is contradicted by recent human data.
Why MOTS-c matters in 2026
Two things changed inside three months. In late February 2026, Hudson Biotech registered NCT07505745, a Phase 2a, randomized, double-blind, placebo-controlled study of subcutaneous native MOTS-c in 120 adults with prediabetes and overweight/obesity, primary endpoint Matsuda Index of insulin sensitivity. It is the first interventional human trial of native MOTS-c in the eleven years since the peptide was discovered. Around the same time, HHS Secretary Kennedy announced that MOTS-c (along with thirteen other peptides previously sitting on the FDA 503A Category 2 prohibition list) would be reclassified to Category 1, freeing compounding pharmacies to prepare it against a prescription. The formal rule has not yet been published in the Federal Register, so the prohibition is still legally in force.
Both moves were structural; neither was driven by new clinical evidence. The reclassification was a policy decision under the Kennedy "health freedom" framing. The trial was financed and run because Hudson Biotech, a peptide-focused biotech, judged the molecule clinically interesting enough to bet on. Neither event tells you anything about whether MOTS-c works in humans.
The gray-market reality is what most readers actually face. U.S. peptide imports from China nearly doubled across 2025, customs seizures climbed sharply through Q1 2025, and 10 mg vials of MOTS-c can be ordered to a residential address for $25-37. Independent testing of internet-purchased research peptides has documented around 30% incorrect amino acid sequences and 65% endotoxin contamination above safety thresholds. Some users who report no effect may simply be injecting the wrong molecule. WADA prohibits MOTS-c at all times under S4.4.1 (Metabolic Modulators, AMPK activators); there is no Therapeutic Use Exemption pathway because there is no approved therapeutic use to exempt against.
Mechanism: a mitochondrial peptide that talks to the nucleus
The MOTS-c story is biologically unusual. Most peptides are encoded by nuclear DNA, translated in the cytoplasm, and act on receptors. MOTS-c is encoded inside the mitochondrial 12S ribosomal RNA gene (MT-RNR1); it is a mitochondrially encoded peptide with a 16-residue sequence (MRWQEMGYIFYPRKLR) that is 100% conserved across humans, mice, rats, and monkeys. That conservation alone is unusual for a peptide of this size and suggests it is doing something the body considers worth keeping.
Three mechanism papers anchor the literature:
Folate-AICAR-AMPK (the original mechanism). The discovery paper showed MOTS-c disrupts the folate-methionine cycle, accumulates AICAR, and activates AMPK by phosphorylating Thr172; the same site metformin acts on. Downstream effects include GLUT4 translocation to the muscle membrane (glucose uptake), suppression of hepatic gluconeogenesis (PEPCK and G6Pase down), and PGC-1alpha upregulation (mitochondrial biogenesis). High-fat-diet mice given 5-15 mg/kg intraperitoneal MOTS-c showed roughly 30-50% improvement in insulin sensitivity and prevention of weight gain (Lee et al., 2015, Cell Metabolism, PMID 25738459). This is the founding paper for every metabolic claim attached to MOTS-c.
Nuclear translocation under stress. Under glucose restriction or oxidative stress, MOTS-c moves from the cytoplasm into the nucleus, binds chromatin, and regulates expression of antioxidant and metabolic adaptation genes; Nrf2 pathway targets in particular (Kim et al., 2018, Cell Metabolism, PMID 29983246). This is paradigm-shifting biology: a mitochondrial peptide acting as a retrograde nuclear signal. It is also the part of the story with the least human validation.
CK2 direct binding. Casein kinase 2 was identified as a direct molecular target; MOTS-c binds CK2, activates it, and CK2 in turn inhibits PTEN, enhances PI3K-AKT, activates mTORC2, and reduces myostatin signaling (Kumagai et al., 2024, iScience, PMID 39559755). The naturally occurring K14Q variant shows about 40% reduced CK2 binding, which is the mechanistic basis for the reported enrichment of K14Q in Japanese centenarians.
Late-life physical decline (animal). The most-cited "anti-aging" data point: aged mice (23.5 months) given 5 mg/kg MOTS-c IP three times weekly preserved physical performance roughly 50% better than vehicle controls across grip, gait, and metabolic measures (Reynolds et al., 2021, Nature Communications, PMID 33473109). This is the paper most longevity influencers cite when claiming "exercise in a bottle." It is real data, in mice, and it has not been replicated in humans.
What is real here: a coherent, multi-pathway mitochondrial-derived signaling story with a clear molecular target. What is not real: any claim that any of this has been demonstrated in a human dosing study.
The animal / human evidence gap
The hardest section of any honest MOTS-c article. The animal literature is large; 90+ studies, mostly positive, expanding into cardiac protection, muscle atrophy, liver fibrosis, age-related metabolic decline, and a long tail of acute injury models. The human literature is also large by count, twelve-plus published studies, but every one of them measured endogenous circulating MOTS-c. None of them administered exogenous MOTS-c and reported outcomes.
The published human data, in summary:
- Acute exercise raises endogenous MOTS-c. A 45-minute cycling bout in 10 healthy adults produced roughly a 40% increase in circulating MOTS-c (von Walden et al., 2021, J Appl Physiol, PMID 34351816). This is the most-cited human MOTS-c paper. It says exercise activates the system you would be trying to mimic by injection; not that injection works.
- Chronic exercise raises endogenous MOTS-c. A 16-week aerobic-plus-resistance program in 82 breast cancer survivors produced sustained MOTS-c elevation (Dieli-Conwright et al., 2021, Sci Rep, PMID 34413391).
- The obesity paradox. A 2024 systematic review and meta-analysis of MOTS-c across metabolic states found MOTS-c is significantly reduced in type 2 diabetes (standardized mean difference -0.89) but significantly increased in obesity (SMD +0.51) (Zhou et al., 2024, Diabetol Metab Syndr, PMID 39160573). A 2026 follow-up study confirmed MOTS-c is elevated in obese adults at baseline and remains elevated after weight loss (Yoon et al., 2026, J Clin Transl Endocrinol, PMID 41551324). MOTS-c is also elevated in acute coronary syndrome and predicts adverse events. The simple "low MOTS-c causes metabolic disease, so replace it" framing, which is the rationale almost every gray-market vendor uses, is contradicted by the human observational record.
- One mechanism trial in mice supports the exercise stack claim. Combined MOTS-c plus exercise produced larger AMPK-pathway and insulin-sensitivity improvements than either alone (Yang et al., 2021, BBA Mol Basis Dis, PMID 33722744). This is animal data, but it is the cleanest evidence for the "MOTS-c amplifies exercise" claim.
The Bradford Hill framework, the standard tool for assessing causal claims, caps animal-to-human extrapolation at preliminary evidence regardless of how many rodent papers accumulate. Two stars out of five is the ceiling. A ninety-first mouse study does not move MOTS-c to "human evidence." The Sports Medicine review of approved and unapproved peptides (Mendias & Awan, 2026, Sports Med, PMID 41966639) classifies MOTS-c as a peptide where "rigorous human safety data are scarce" and explicitly names the role of social media in amplifying placebo effect for compounds in this class.
The piece of evidence that could move MOTS-c past the ceiling, NCT07505745, exists, but reads out around 2028.
What people actually use
Three different "MOTS-c doses" exist, and none of them line up.
| Source | Dose | Route | Notes |
|---|---|---|---|
| Animal standard (most studies) | 5-15 mg/kg/day | Intraperitoneal | The dose nearly all animal data uses |
| Allometric human equivalent (5 mg/kg mouse) | ~25-30 mg/day (70 kg) | , | Theoretical only, never validated in humans |
| 2024 community consensus | 5 mg 2-3x/week | SubQ | The "Seeds protocol" range, popular through 2024 |
| 2026 community trend | 1-3 mg daily | SubQ | MESO-Rx and forum reports converging on lower doses |
| CB4211 analog (NCT03998514) | Subcutaneous, multiple doses tested | SubQ | Different molecule; ALT/AST reductions, primary liver fat endpoint failed |
The community has been quietly de-escalating doses through 2025 and 2026. The 2024-era "5 mg three times a week" protocols are giving way to 1-3 mg daily reports. Whether this reflects a real signal about optimal dosing or just collective fatigue with injection-site burning is unknown; neither protocol has any pharmacokinetic basis in humans. Peak plasma, Cmax, AUC, half-life, distribution volume, and protein binding are all unmeasured. Half-life is estimated at 4-6 hours from peptide-size inference. Whether subcutaneous administration achieves equivalent tissue exposure to the intraperitoneal route used in every animal study is unknown.
If you want to walk reconstitution math against a specific vial size, the peptide reconstitution calculator lets you do that without us putting a recommended dose on the page. We are not telling you what to take. We are showing you what the conversion math looks like for the inputs you choose.
Safety and regulatory
The honest summary of MOTS-c safety: zero published human dosing trials, zero FAERS reports (because MOTS-c has never been an FDA-approved drug, not because safety has been established), and an animal record up to 18 months of chronic dosing in mice with no organ toxicity, no increased mortality, and a wide therapeutic index. CB4211, a MOTS-c analog, not the native peptide, was well-tolerated in 88 NAFLD subjects (NCT03998514) with no serious adverse events, but the primary hepatic endpoint (liver fat by MRI-PDFF) did not separate from placebo. Persistent injection-site reactions were noted. Transferability to native MOTS-c is uncertain.
Three specific cautions are worth naming.
Injection-site reactions are near-universal. Community reports describe MOTS-c injections as notably more painful than other peptides, with flushing, redness, and occasional hives; consistent with mast cell activation rather than infection. The CB4211 trial documented persistent injection-site reactions across the dose range. These reports are real and consistent across forums.
Cancer is unstudied with chronic AMPK activation. AMPK has tumor-context-specific effects; anti-tumor in some models (ovarian cancer, hepatocellular carcinoma in animal data), pro-survival in others. There are no human cancer-bearing studies of MOTS-c. The cautious read is to avoid in active cancer, recent cancer history, and undiagnosed populations where occult malignancy might be present, until human trial data exists.
The obesity and ACS paradoxes change the safety calculus. If MOTS-c is elevated (not depleted) in obesity and acute coronary syndrome, and recent human observational data shows both, then "more MOTS-c is better" is not an obviously safe assumption. Supraphysiological dosing in populations where endogenous levels are already elevated has no precedent and no monitoring framework.
Sport, military, and prescription status. WADA prohibits MOTS-c at all times under S4.4.1 (Metabolic Modulators; AMPK activators) on the 2025 and 2026 Prohibited Lists. There is no TUE pathway. The U.S. military Operation Supplement Safety classifies it as prohibited. The FDA placed MOTS-c on 503A Category 2 in September 2024; the announced reclassification to Category 1 is not yet in effect. Australia's TGA and the EMA have no marketing authorization on file. For competitive athletes, military service members, and anyone subject to drug testing, the regulatory picture is unambiguous. For everyone else, the absence of FDA approval should be read as "this compound has not gone through the trials a drug normally goes through"; not as proof of unusual risk, but also not as license.
The compound-quality risk for gray-market sourcing is its own safety category. Demand a certificate of analysis with HPLC purity above 98%, mass spectrometry confirming molecular weight 2174.5 Da, endotoxin testing under 1.0 EU/mg, and sterility confirmation. "99% Pure" labels with no batch documentation are unreliable on their face.
Frequently asked
Is MOTS-c FDA-approved? No. MOTS-c was placed on the FDA 503A Category 2 list in September 2024, prohibiting compounding pharmacies from preparing it for human use. HHS announced a Category 1 reclassification on February 27, 2026, but the formal rule has not been published in the Federal Register, so the prohibition technically still stands. Category 1 would allow compounded preparation against a prescription; it would not mean drug approval.
How much human data is there? Zero completed human dosing trials of native MOTS-c. The first-ever Phase 2a interventional study (NCT07505745, Hudson Biotech, N=120, prediabetes/obesity, SubQ) began recruiting in February 2026 with results expected around 2028. A MOTS-c analog called CB4211 completed a Phase 1a/1b in NAFLD with mixed topline results; well-tolerated, but the primary liver fat endpoint did not separate from placebo. All other "human studies" on MOTS-c measured endogenous blood levels, not exogenous dosing.
Is MOTS-c banned in sports? Yes. The World Anti-Doping Agency prohibits MOTS-c at all times under Section S4.4.1 (Metabolic Modulators; AMPK activators) on the 2025 and 2026 Prohibited Lists. There is no Therapeutic Use Exemption pathway because MOTS-c has no approved therapeutic use anywhere.
Doesn't exercise already raise MOTS-c? Yes; by about 40% acutely after a single endurance bout in healthy humans (von Walden et al., 2021, PMID 34351816). Exercise is the validated way to raise circulating MOTS-c. Whether injecting exogenous MOTS-c on top of an exercise stimulus adds anything has never been tested in humans, and the MOTS-c level you reach in plasma after a SubQ injection is not the same biological signal as MOTS-c secreted from working muscle into local tissue.
What's the obesity paradox? The simple story is "low MOTS-c causes metabolic disease, so replace it." The data don't support that story. A 2024 systematic review and meta-analysis (Zhou et al., PMID 39160573) found MOTS-c is reduced in type 2 diabetes but increased in obesity, and a 2026 human study (Yoon et al., PMID 41551324) confirmed MOTS-c is elevated in obese adults and stays elevated after weight loss. MOTS-c is also elevated in acute coronary syndrome. The "deficiency replacement" framing, the entire rationale most people use to start MOTS-c, looks wrong, or at minimum incomplete.
This article reflects the state of the literature as of April 2026. Every PMID was verified live against PubMed before publication by the same INT-01 citation guardrail that gates the calculators on this site.